MINISTER for Health Greg Hunt has announced the funding of immunotherapy medicine Keytruda (pembrolizumab) for first-line treatment of metastatic non-small cell lung cancer (NSCLC) to take effect 01 Nov.
Without PBS subsidy it would cost over $11,300 per script or $188,000 a year, Hunt said.
This indication-extension listing was recommended at the Jul 2018 Pharmaceutical Benefits Advisory Committee (PBAC) meeting.
See more at health.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 30 Oct 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Oct 18
